At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Ixabepilone +1 moredrug
Likely dose
Ixabepilone 16 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study
In Brief
A Phase 2 clinical trial evaluating Ixabepilone and Prostatectomy for Prostate Cancer. Completed, enrolled 16 participants across 1 site.
Detailed Summary
Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy 2-8 weeks after completion(standard of care and not a part of study)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsRhode Island Hospital, The Miriam Hospital
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartFeb 2009
Primary CompletionMar 2011
Study CompletionDec 2016
TodayJul 2026
First PostedJan 23, 2009
Enrollment StartFeb 1, 2009
Primary CompletionMar 1, 2011
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.4 years ago
Interventions
Ixabepilonedrug
Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
Prostatectomyprocedure
Prostatectomy 2-8 weeks after completion \*\*\*this was standard of care and not a part of the study\*\*